We call on the Government to fund NHS access to Omaveloxolone in the UK. We believe the drug should also be considered under the HST programme, which we feel is the only appraisal route which reflects the realities of Friedreich's Ataxia. This is a degenerative disease & time is of the essence.

Friedreich's Ataxia patients need access to the drug Omaveloxolone, the only drug available for this disease. Without treatment, this degenerative disease can get worse. Patients & families may have to see their loved ones deteriorate when they are aware there is a drug available to stop the progression of this disease & in many cases, to improve the symptoms. The drug is available in EU countries & America. It passed the safety test in April 2025 and we believe it should be available on the NHS!